Prebiotics and Metformin Improve Gut and Hormones in Type 2 Diabetes in Youth (MIGHTY-fiber)

Phase

Condition

Diabetic Retinopathy

Diabetes Mellitus, Type 2

Diabetic Neuropathy

Treatment

N/A

Clinical Study ID

NCT04209075

200018

20-DK-0018

Ages 10-25
All Genders

Study Summary

Background:

Metformin is a pill youth with type 2 diabetes take. It can cause side effects like diarrhea and upset stomach. Researchers want to see if a fiber supplement can help decrease these side effects.

Objective:

To see if a prebiotic fiber supplement helps improve the gastrointestinal side effects of people taking metformin and helps with their blood sugars.

Eligibility:

People ages 10-25 with type 2 diabetes who are taking or will take metformin

Design:

Participants will be screened with:

Physical exam

Medical history

Blood and urine tests

Meeting with a nutritionist

Participants will stop taking all diabetes medication for 1 week. They will then take metformin by mouth for 1 week. They will be randomly assigned to take either a fiber supplement or a placebo by mouth during the same week. They will then stop all study treatments for 2-3 weeks. Then they will restart metformin for 1 week. The groups that received the fiber versus the placebo will be reversed. All participants will then continue taking metformin and take the fiber for 1 month.

Participants will have 6 visits over about 2 months. These will include:

Blood and urine tests

Meal tests: A plastic tube will be inserted in the participant s arm vein for blood draws. They will drink a special meal.

Dual-energy x-ray absorptiometry (DXA) scan: Participants will lie on their back while the scan measures their body fat and muscle.

While they are home, participants will:

Fill out daily surveys online

Wear daily activity and blood sugar monitors

Collect their stool

Eat only certain foods for two 1-week periods...

Eligibility Criteria

Inclusion

INCLUSION CRITERIA:

Age 10-25 years
Pubertal or post-pubertal: Girls - Tanner stage IV-V breast; Boys - Testicularvolume >10cc
Diagnosis of type 2 diabetes by American Diabetes Association (ADA) guidelines [36] or with established diagnosis previously treated with metformin.
Negative test for diabetes-related autoantibodies (glutamic acid decarboxylase 65and tyrosine phosphatase-related islet antigen 2 (IA-2)) documented in NIH CRISchart or via outside laboratory assessment within the last 10 years.
Hemoglobin A1C <8% at study initiation

Exclusion

EXCLUSION CRITERIA:

Pregnancy or breastfeeding
Allergy to study medications
Allergy or self-reported intolerance to blueberry, pomegranate, or oats, soy, glutenor dairy products.
Chronic insulin therapy or insulin use within the last 3 months
Treatment with other medications which are known to affect the parameters under study,including antibiotics within the last month, immunosuppressants, proton-pumpinhibitors, supraphysiologic systemic steroids, probiotic or prebiotic supplements
Heavy yogurt consumption (2 or more servings of >=6 oz per day)
Chronic GI disease, gastric bypass surgery, cancer diagnosis or autoimmune disease
Metabolic derangement such as metabolic acidosis, severe hyperglycemia (fasting bloodglucose >= 200mg/dL), and/or liver enzymes > three times the upper limit of normal.
Any other condition that, in the opinion of the investigators, will increase risk tothe subject, or impede the accurate collection of study-related data.
Body weight >= 450lbs
Body weight <=58kg
Hemoglobin concentration <10g/dL

Study Design

March 10, 2020

July 15, 2021

Study Description

Metformin is the most widely prescribed anti-diabetes medication in the world and the first-line therapy for treating type 2 diabetes (T2D) in youth and adults. However, metformin s glucose-lowering ability is variable in clinical practice, and efficacy is further limited by poor medication adherence because of metformin-associated adverse effects. Gastrointestinal (GI) symptoms such as bloating, abdominal discomfort, cramping, and diarrhea are the most common side effects associated with metformin use occurring in up to 80% of individuals at drug initiation and up to 30% in individuals on chronic treatment. In youth with type 2 diabetes, the burden of metformin-associated side effects is high because metformin is the only oral FDA-approved for treatment and there are no other oral alternatives. Therefore, identifying ways to mitigate these GI side effects, especially in youth with type 2 diabetes, is of high clinical significance. New data suggest that metformin-induced changes in the gut and/ or the microbiome may be related to both its beneficial (glucose-lowering) and adverse effects. To address this clinical challenge, prebiotic fibers that are non-digestible food ingredients, may help to improve metformin tolerability by increasing beneficial bacteria and stool metabolites, such as short chain fatty acid (SCFA) stool concentrations. This pilot study will test the hypothesis that a prebiotic microbiome modulator (MM) - containing prebiotic fibers and polyphenols - will reduce GI side effects of metformin at time of initiation and change the stool metabolite profile in youth and young adults with T2D treated with metformin, age 10-25 years who are not on insulin therapy. The 9-week study will have 2 phases and 6 outpatient visits at the NIH Clinical Center. Phase 1 is a 5-week randomized double blind cross-over trial with two 1-week intervention periods (metformin + prebiotic and metformin + placebo) during which subjects will eat a standardized diet. Phase 2 will occur immediately following phase 1 in which participants will start an open-label 4-week intervention with metformin and the prebiotic MM.

Connect with a study center

National Institutes of Health Clinical Center
Bethesda, Maryland 20892
United States
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.